Targeting “Undruggable” Proteins That Drive Cancer: AACR grantee Raymond E. Moellering, PhD, of the University of Chicago, uses chemistry to build “molecules that can go after undruggable protein targets” to treat cancers.
Learn More in AACR StoriesCancer is not a single disease, but rather a collection of diseases all characterized by the uncontrolled proliferation of cells.
Learn MoreResearch-driven advances in our understanding of the immune system invigorated the field of cancer immunology and established immunotherapy as the fifth pillar of cancer medicine.
Read the ReportMore than 310,000 women in the United States are expected to be diagnosed with breast cancer this year. Read about prevention, screening, and treatment options for breast cancer.
Learn MoreMembers of the AACR Associate Member Council interviewed National Cancer Institute Director Kimryn Rathmell about her career and lessons for the next generation of cancer researchers.
Read the AACR BlogThe current issue of Leading Discoveries magazine features articles on AACR President Patricia M. LoRusso’s efforts to improve clinical trials, an AACR initiative on communicating science effectively, and more.
Read Leading DiscoveriesYour donation to the American Association for Cancer Research will help fund early-career investigators. Fund the future of cancer research today.
Donate NowRegister now to get the lowest rate for the AACR Annual Meeting 2025 (April 25-30, Chicago).
Deadline: January 3
The AACR Cancer Progress Report 2024 highlights research-driven advances against the collection of often devastating diseases we call cancer.
Learn MoreThe AACR and its more than 58,000 members worldwide are advancing a scientifically bold agenda against the collection of diseases we call cancer.
Learn MoreDr. LoRusso, AACR President 2024-2025, explains that basic cancer research is essential to accelerating advances in cancer science and medicine.
Learn Morepercent decrease of the overall age-adjusted cancer death rate in the U.S. from 1991 to 2021
Learn Moretherapeutics were approved for new or expanded uses by the FDA from July 1, 2023, to June 30, 2024
Learn Moremillion cancer survivors in the U.S. are living with, through, and beyond their disease thanks to research
Learn More